Medline $MDLN Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Medline (NASDAQ:MDLN) by 14.9% during the 1st quarter, HoldingsChannel reports. The firm owned 98,575 shares of the company’s stock after selling 17,227 shares during the period. The Manufacturers Life Insurance Company’s holdings in Medline were worth $4,387,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of MDLN. Perigon Wealth Management LLC purchased a new stake in shares of Medline during the fourth quarter worth approximately $211,000. Sound Income Strategies LLC purchased a new position in Medline in the 4th quarter valued at $25,000. Massachusetts Financial Services Co. MA acquired a new position in Medline in the 4th quarter valued at $429,544,000. Baillie Gifford & Co. acquired a new position in Medline in the 4th quarter valued at $437,236,000. Finally, Mass General Brigham Inc purchased a new position in Medline during the 4th quarter worth $1,104,000.

Medline Stock Performance

Shares of MDLN stock opened at $34.51 on Friday. The stock has a fifty day moving average price of $38.24 and a 200 day moving average price of $41.77. The stock has a market cap of $45.34 billion and a PE ratio of 107.84. Medline has a 1 year low of $32.81 and a 1 year high of $50.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.41.

Medline (NASDAQ:MDLN) last posted its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.18. The firm had revenue of $7.68 billion during the quarter. Sell-side analysts forecast that Medline will post 1.49 earnings per share for the current fiscal year.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter revenue of $7.7 billion, up 11.6% year over year, while adjusted EBITDA rose 13.4% to $1.06 billion. Adjusted EPS of $0.50 exceeded the $0.32 analyst consensus. Medline Reports Second Quarter and First Six Months 2026 Results
• Positive Sentiment: Management raised its 2026 organic-sales growth outlook to 9%-10% from 8.5%-9.5%, citing strong demand, new customer wins and existing-customer growth. Operating cash flow and free cash flow also improved substantially in the first half.
• Positive Sentiment: BTIG maintained a Buy rating and $55 price target, while Truist and Stifel retained Buy ratings even after lowering their targets to $47 and $45, respectively. These targets imply analysts still see meaningful upside if Medline executes on its growth plans. BTIG Medline Rating
• Neutral Sentiment: Medline recorded $243 million of net IEEPA tariff-refund benefits in the quarter, partially offset by $89 million in customer repayments. Investors may view this as a temporary benefit rather than a recurring improvement in earnings.
• Negative Sentiment: The company lowered full-year adjusted EBITDA guidance to $3.3-$3.4 billion from $3.5-$3.6 billion. Management cited inflation, higher operating investments, quality-remediation costs, retail-channel weakness and geopolitical pressures.
• Negative Sentiment: Second-quarter net income fell 58.3% to $139 million, and diluted GAAP EPS was only $0.07. A $336 million loss related to the Tracy, California distribution-center fire, along with higher expenses and costs, sharply reduced reported profitability.
• Negative Sentiment: Securities-law firms announced investigations following an FDA warning letter that reportedly identified significant violations. Although the investigations are preliminary, potential regulatory action, litigation costs and operational disruption add to investor uncertainty. Medline Investigation Alert

Insider Buying and Selling at Medline

In other Medline news, insider Jessi L. Corcoran acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average cost of $34.15 per share, for a total transaction of $170,750.00. Following the transaction, the insider directly owned 5,000 shares of the company’s stock, valued at approximately $170,750. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Douglas P. Golwas sold 100,000 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the completion of the sale, the insider directly owned 23,899 shares in the company, valued at approximately $878,766.23. The trade was a 80.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.81% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $47.00 target price on shares of Medline in a report on Thursday. Deutsche Bank Aktiengesellschaft set a $37.00 price target on shares of Medline in a report on Thursday. Truist Financial reduced their price objective on shares of Medline from $56.00 to $47.00 and set a “buy” rating for the company in a research report on Thursday. Sanford C. Bernstein dropped their target price on Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Finally, Robert W. Baird set a $42.00 target price on Medline in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $48.50.

Medline Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.